What are essential documents in a clinical trial, and what goes in the investigator site file?
Essential records are the documents and data, in any format, that let the trial be managed and let anyone evaluate how it was run and whether its results can be trusted; ICH E6(R3) lists them in Appendix C (ICH E6(R3) Glossary).
The site keeps its essential records in a repository often called the investigator site file, or regulatory binder, and the sponsor keeps its own in the trial master file (ICH E6(R3) C.2.3).
What usually goes in the investigator site file
The exact list depends on the trial design and the sponsor, and E6(R3) asks for records proportionate to their importance (ICH E6(R3) C.1.1). Most site files hold:
- The protocol and every amendment, with the investigator's signature.
- The Investigator's Brochure or product information, and safety updates.
- IRB or ethics committee approvals of the protocol, consent materials and advertisements, and their correspondence.
- Every version of the informed consent form the IRB has given a favorable opinion to.
- The delegation log, staff CVs, licenses and training records.
- Investigational product records: receipt, storage, dispensing, accountability and return.
- Laboratory certifications and normal ranges, and monitoring visit logs.
- Signed consent forms and source records, often kept in participants' files rather than the binder itself.
How the records must be kept
- Identifiable and version controlled, with authors, reviewers, dates and signatures where needed (ICH E6(R3) C.2.1).
- With a record of where each essential record is, including source records (ICH E6(R3) C.2.4).
- Complete, readable, readily available and directly accessible to regulators, monitors and auditors, with any change traceable (ICH E6(R3) C.2.6).
- When a copy replaces the original, the copy must meet the requirements for a certified copy (ICH E6(R3) C.2.9).
How long to keep them
The investigator keeps essential records for the period the regulations require or until the sponsor says they are no longer needed, whichever is longer (ICH E6(R3) 2.12.12).
For US drug studies, the investigator keeps records for 2 years after FDA grants a marketing application for the indication, or, if no application is filed or none is granted, until 2 years after the investigation is discontinued and FDA is notified (21 CFR 312.62(c)). The sponsor's agreement often asks for longer.
Questions people also ask
What is the difference between the TMF and the ISF?
The trial master file is the sponsor's repository of essential records; the investigator site file is the site's (ICH E6(R3) C.2.3). Some records live in both, and some only in one, for example those holding confidential participant information stay at the site (ICH E6(R3) C.2.10).
Can the investigator site file be electronic?
Yes. E6(R3) defines essential records in any format, and the storage system must allow identification, version history, search and retrieval (ICH E6(R3) C.2.4). In the US, electronic records used to meet FDA requirements fall under 21 CFR Part 11 (21 CFR 11.1(b)).
Who is responsible for the site file?
The investigator or institution. They should keep control of all essential records generated by the site (ICH E6(R3) 2.12.11) and tell the sponsor who is responsible for them during the retention period (ICH E6(R3) 2.12.13).
Is a regulatory binder the same as an investigator site file?
In practice, yes. Regulatory binder is the common US name for the site's essential records file.
Primary sources
- ICH E6(R3) Guideline for Good Clinical Practice, final version adopted 6 January 2025 (ICH): https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf
- 21 CFR 312.62: Investigator recordkeeping and record retention (eCFR): https://www.ecfr.gov/current/title-21/section-312.62
- 21 CFR 11.1: Scope of Part 11 (eCFR): https://www.ecfr.gov/current/title-21/section-11.1
Last reviewed
2026-11-12